Healthcare entity
All 1 tracked stories fall under one category: market-trends. ATG-022 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. ATG-207 appears in 1 tracked Healthcare story from August 23, 2026.
Last mentioned: 4h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. ATG-022 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. ATG-207 appears in 1 tracked Healthcare story from August 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ATG-207. Shared-story counts are live from our verified record — not editorial picks.
Press Release Distribution
Company issues PRNewswire release summarizing the summit highlights.
Evercore Summit Presentation
Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
ATG-207 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
